CAPLIN POINT LABORATORIES LTD

Registered Office: "Narbavi", # 3, Lakshmanan Street, T.Nagar, Chennal 600 017
UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31st MARCH 2011

	· · · · · · · · · · · · · · · · · · ·				Unai-ditad	
		Unaudited Three months ended		Unaudited Nine months ended Mor 31,		Audited Year ended
	Particulars					
		Mai				June 30,
		2011	2010	2011	2010	2010
				(Rs in lakhs)	
1	Income	100404	1.000.14	6.060.07	1700.07	6,070.71
	a. Sales/ income from operations	1,804.26	1,999.16	5,350.87 239.30	4,722.07	0,070.71
	b. Share of profits in LLP	239.30	- 1		4.722.07	6,070.71
	c. Total	2,043.56	1,999.16	5,590.17	4,722.07	6,070.71
		-				
2	Expenditure a. (Increase)/decrease in stock in trade and work in progress	(195.10)	79.62	(264.16)	153.26	128.74
	b. Consumption of raw materials	606.51	591.21	1,757.93	1,519.00	2,054,34
		1,044.05	879.06	2,573.26	2,097.05	2,647,19
	c. Purchase of traded goods	0.15	0.05	0.52	1.52	1.52
	d. Excise Duty paid	116.32	58.99	292.89	187.98	269.34
	e. Employees cost	29.62	23.79	84.81	68.53	92.47
	f. Depreciation	29.20	29.20	87.60	87.60	116.80
	g. Amortisation of Goodwill		128.70	424.32	360.27	488.92
	h. Other Expenditure	161.47	1,790.62	4,957.17	4,475.21	5,799.32
	i. Total	1,792.22	208.54	633.00	246.86	271.39
3	Profit(+)/Loss(-) from Operations before other Income and Interest (1-2)	251,34		113.07	119.97	176.81
4	Other Income	40.48	29.26		366.83	448.20
5	Profit(+)/Loss(-) before Interest (3+4)	291.82	237.80	746.07		(83.36)
6	Interest Expenses	(24.43)	(17.70)	(74.85)	(61.37)	
7	Profit(+)/Loss(-) from Ordinary Activities before tax (5-6)	267.39	220.10	671.22	305.46	364.84
8	Provision for Taxation	(8.00)	7.65	(102.00)	(11.35)	(31.35)
	Provision for Taxation - earlier years		-	1.59		10.071
	Deferred Tax Provision	(9,91)	2.42	(39.03)	2.17	(0.31)
9	Net Profit(+)/Loss(-) from Ordinary Activities after tax (7-8)	249.48	230.17	531.78	296.28	333.18
10	Extraordinary Item (net of tax expense)					
11	Net Profit(+)/Loss(-) for the period (9-10)	249.48	230.17	531.78	296.28	333.18
12	Paid up Equity Share Capital (Face value of the share - Rs 10/- each)	1,511.00	1,511.00	1,511.00	1,511,00	1,511.00
13	Reserves excluding Revaluation Reserves as per Balance Sheet of previous	-	-	-	<u>-</u>	659.1 <i>7</i>
	accounting year					
14	Earnings/(Loss) Per Share (EPS)	_				
	(a) Basic/Diluted EPS before Extraordinary items (in Rupees)	1.65	1,52	3.52	1.96	2.21
	(b) Basic/Diluted EPS after Extraordinary items (in Rupees)	1.65	1.52	3.52	1.96	2.21
15	Public Shareholding					
	- Number of Shares	5.490.967	5,490,967	5,490,967		5,490,967
	- Percentage of Shareholding	36.34%	36.34%	36.34%	36.34%	36.34%
16	Promoters and promoter group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	Nil	Nil	Nîl	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and	- ''				
	promoter group)	-	-		-	-
	- Percentage of shares (as a % of the total share capital of the company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of Shares	9,619,033	9,619,033	9,619,033	9,619,033	9,619,033
	- Percentage of shares (as a % of the total shareholding of promoter and					
	promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	63.66%	63.66%	63.66%	63.66%	63.66%
			· ·			· · · ·
					_	_

Notes:

- 1) The Company operates in one segment only.
- 2) Amortisation of Goodwill, which has arisen out of Amalgamation of May India Laboratories P Ltd with this company with effect from 1st April 2006, is being written off over a period of 5 years.
- 3) The above standalone unaudited financial results were considered and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 30th April 2011.
- 4) The statuory auditors have carried out a limited review of the results for the quarter ended 31st March 2011.
- 5) No investor complaints were pending at the beginning and end of the quarter. 22 complaints were received by the Company during the quarter ended 31st March 2011 and the same were resolved.
- 6) The net profit of the current quarter includes share of profit from Argus Salud Pharma LLP, in which controlling interest is held by the Company.
- 7) Prior year / period figures are regrouped / rearranged wherever necessary.

Place: Chennai Dated: 30.04.2011 M. Jayapal Managing Director

T00 🗗